Cancer Neoantigens

Annual Review of Immunology, Journal Year: 2018, Volume and Issue: 37(1), P. 173 - 200

Published: Dec. 14, 2018

Malignant transformation of cells depends on accumulation DNA damage. Over the past years we have learned that T cell-based immune system frequently responds to neoantigens arise as a consequence this Furthermore, recognition appears an important driver clinical activity both cell checkpoint blockade and adoptive therapy cancer immunotherapies. Here review evidence for relevance in tumor control biological properties these antigens. We discuss recent technological advances utilized identify neoantigens, recognize them, individual patients. Finally, strategies can be employed exploit interventions.

Language: Английский

---

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

Cancer Cell, Journal Year: 2020, Volume and Issue: 38(6), P. 788 - 802

Published: Sept. 17, 2020

Language: Английский

---

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy

Frontiers in Immunology, Journal Year: 2018, Volume and Issue: 9

Published: Jan. 22, 2018

Recent advances in cancer treatment have emerged from new immunotherapies targeting T-cell inhibitory receptors, including CTLA-4 and PD-1. In this context, anti-CTLA-4 anti-PD-1 monoclonal antibodies (mAb) demonstrated survival benefits numerous cancers, melanoma non-small-cell lung carcinoma (NSCLC). PD-1-expressing CD8+ T lymphocytes appear to play a major role the response these immune checkpoint inhibitors (ICI). Cytotoxic (CTL) eliminate malignant cells through recognition by receptor (TCR) of specific antigenic peptides presented on surface histocompatibility complex class I (MHC-I)/beta-2-microglobulin (beta2m) complexes, killing target cells, mainly releasing content secretory lysosomes containing perforin granzyme B. adhesion molecules and, particular, lymphocyte-function-associated antigen-1 (LFA-1) CD103 integrins, their cognate ligands, respectively, intercellular molecule 1 (ICAM-1) E-cadherin, are involved strengthening interaction between CTL tumor cells. Tumor-specific been isolated tumor-infiltrating (TIL) peripheral blood (PBL) patients with varied cancers. TCRbeta-chain gene usage indicated that identified vitro selectively expanded vivo at site compared autologous PBL. Moreover, functional studies mediate human leukocyte antigen (HLA-I)-restricted cytotoxic activity toward Several them recognize truly tumor-specific antigens (TSA) encoded mutated genes, also known as neoantigens, which likely key anti-tumor CD8 immunity. Accordingly, it has shown presence directed neoantigens is associated patient immunotherapies, ICI, adoptive cell transfer (ACT) dendritic cell-(DC)-based vaccine. These mutation-derived open up perspectives for development effective second-generation therapeutic vaccines.

Language: Английский

---

Genomic correlates of response to immune checkpoint blockade

Nature Medicine, Journal Year: 2019, Volume and Issue: 25(3), P. 389 - 402

Published: March 1, 2019

Language: Английский

---

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

Cell, Journal Year: 2020, Volume and Issue: 183(3), P. 818 - 834.e13

Published: Oct. 1, 2020

Language: Английский

---